RxDoctor Payments Data

John Lawrence, MD

Advanced Heart Failure and Transplant Cardiology · Lafayette, LANPI 1114345014

Payments from drug & device makers

What this record shows

24 manufacturers reported payments, led by Edwards Lifesciences at 34.5% of the total.

$16,748in general payments, 2019–2025

Across 217 payments — averaging $77.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$6K
  • Medtronic$5K
  • Abbott$4K
  • Abiomed$654
  • Boston Scientific$271
  • Novartis$241
  • plus $1K from 18 others

What the payments were for

  • Travel & lodging$8,46051%
  • Food & beverage$8,28749%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Louisianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$521,788
Medicare patients
1,828
Services billed
5,481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban197$182,297
EntrestoSacubitril/Valsartan103$109,721
JardianceEmpagliflozin60$62,682
XareltoRivaroxaban40$32,088
FarxigaDapagliflozin Propanediol44$30,814
Repatha PushtronexEvolocumab21$17,083
VascepaIcosapent Ethyl33$15,083
NexletolBempedoic Acid21$10,822
Repatha SureclickEvolocumab17$9,173
Metoprolol Succinate170$1,805
Atorvastatin Calcium125$1,392
Rosuvastatin Calcium112$832
Amlodipine Besylate157$766
Valsartan35$737
Carvedilol70$638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$182,297197 claims
NovartisEntresto$241$109,721103 claims
Boehringer IngelheimJardiance$18$62,68260 claims
AstraZenecaFarxiga$19$30,81444 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Louisianaon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →